In the article, “Progress and contrasts of the development of tivozanib for therapy of kidney cancer,” by Gupta and Fishman (Expert Opin. Pharmocother 2011:12(18):2915-2922), an error was identified. The pivotal trial cited in the drug summary box, AXIS trial, was incorrect. The correct trial name should be TIVO-1 NCT 01030783.
Informa Healthcare apologises for any confusion caused.